All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

AMGNAmgen
2Calm
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Signing up patientsPhase 3450 patientsMain results: Sep 25, 2028
RCUSArcus Biosciences, Inc.
0Calm
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
FinishedPhase 31,040 patientsMain results: Aug 28, 2026
URGNUroGen Pharma Ltd.
5Calm
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Signing up patientsPhase 370 patientsMain results: Mar 2027
MRKMerck Sharp & Dohme LLC
5Calm
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Signing up patientsPhase 1/2210 patientsMain results: May 9, 2028
AZNAstraZeneca
0Calm
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Running, no new patientsPhase 2127 patientsMain results: Feb 10, 2027
ADRXADARx Pharmaceuticals, Inc.
0Calm
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Signing up patientsPhase 2240 patientsMain results: Feb 28, 2030
AZNAstraZeneca
0Calm
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Running, no new patientsPhase 247 patientsMain results: Jan 18, 2027
SLSSellas Life Sciences Group
0Calm
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Signing up patientsPhase 1/2160 patientsMain results: Dec 30, 2026
AZNAstraZeneca
0Calm
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Running, no new patientsPhase 3587 patientsMain results: Apr 3, 2023
PFEPfizer
0Calm
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Running, no new patientsPhase 3257 patientsMain results: Oct 30, 2026
VRCAVerrica Pharmaceuticals Inc.
0Calm
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Signing up patientsPhase 3300 patientsMain results: May 2027
ONCBeiGene
2Calm
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
FinishedPhase 1/271 patientsMain results: Dec 7, 2023
MRKMerck Sharp & Dohme LLC
5Calm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Signing up patientsPhase 2140 patientsMain results: Nov 15, 2029
INOInovio Pharmaceuticals
0Calm
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
FinishedPhase 1/235 patientsMain results: May 9, 2025
AZNAstraZeneca
0Calm
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Signing up patientsPhase 1/252 patientsMain results: Mar 29, 2029
AZNAstraZeneca
0Calm
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Running, no new patientsPhase 3607 patientsMain results: Jul 15, 2027
LXEOLexeo Therapeutics
4Calm
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Signing up patientsPhase 226 patientsMain results: Jun 2032
BCTXBriaCell Therapeutics Corporation
0Calm
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Signing up patientsPhase 3404 patientsMain results: Dec 2027
RLMDRelmada Therapeutics, Inc.
0Calm
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Not started yetPhase 3393 patientsMain results: Dec 2029
RLMDRelmada Therapeutics, Inc.
0Calm
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Signing up patientsPhase 270 patientsMain results: Nov 2027
AZNAstraZeneca
0Calm
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Running, no new patientsPhase 2108 patientsMain results: Oct 31, 2028
PFEPfizer
0Calm
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Running, no new patientsPhase 1/237 patientsMain results: Mar 24, 2027
SNYSanofi
0Calm
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Running, no new patientsPhase 3531 patientsMain results: Nov 6, 2024
PYXSPyxis Oncology, Inc
0Calm
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Signing up patientsPhase 1/2220 patientsMain results: Dec 6, 2027
BMYCelgene
10Calm
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Signing up patientsPhase 1/262 patientsMain results: May 31, 2027